Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy

Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients

“…Furthermore, application of POP PK analysis allows the investigation of the effect of different covariates like age, weight, sex, concomitant diseases and co‐administered drugs on drug PK parameters (8). In this study, The POP estimate for CBZ CL was found to be 3·5 L/h, which was consistent with literature reports (9–12), but our sampling was insufficient to estimate the effect of covariates. Previous studies suggest that age could alter CBZ CL especially in children (6, 13), with the CL tending to be higher than in adults (14).…”

Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis

“…Population PK studies of topiramate use in epilepsy to guide the dosing regimen are limited. Population PK models can be important extensions of therapeutic drug monitoring because they allow estimation of individual PK parameters from a large number of patients, but based on a small number of sparsely measured drug concentrations in each patient [10]. In the present study, topiramate CL/F of a typical patient with CLcr of 90 mL/min and dose of 100 mg, was expected to be 1.16 L/h.…”

Population pharmacokinetics of valproate in Chinese children with epilepsy

“…All of the patients or their parents recorded all the dosages administered as well as the times of dosage administration and blood sampling. They were all judged to have had good compliance and the importance of good records was emphasized by their treating physicians [10,11,23] .…”

“…A new way of determining individual doses uses population pharmacokinetics (PPK) and the Bayesian method to obtain individual PK parameters and has avoided the disadvantages of the traditional method. Many successful uses of PPK have been described [7][8][9][10][11] .…”